Dr. Minglei Zhuo 卓明磊
Chief Physician, Associate Professor
Medical Oncology (II), Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized, multidisciplinary comprehensive treatment for lung cancer based on genetic profiling.
Dr. Zhuo holds a medical doctorate from Peking Union Medical College (2002). During doctoral studies, Dr. Zhuo published three SCI papers as first author. Since August 2007, Dr. Zhuo has worked at Peking University Cancer Hospital.
Name order: in Chinese the family name comes first (Zhuo Minglei). Papers usually list the name as Minglei Zhuo or Zhuo M.
Selected publications
103 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Curr Oncol, 2026 (senior author): Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. PubMed 42187575
- Clin Transl Oncol, 2024 (senior author): Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis. PubMed 38329610
- BMC Public Health, 2024 (senior author): Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study. PubMed 38789981
- Chin J Cancer Res, 2022 (senior author): Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China. PubMed 36199537
- Zhongguo Fei Ai Za Zhi, 2022 (senior author): [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience]. PubMed 35899447
- Thorac Cancer, 2021 (senior author): Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. PubMed 33787090
- Zhongguo Fei Ai Za Zhi, 2021 (senior author): [Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer]. PubMed 33819964
- Asia Pac J Clin Oncol, 2020 (first author): The adverse events associated with combination immunotherapy in cancers: Challenges and chances. PubMed 32786161
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion